177 reports of this reaction
3.5% of all POLYMYXIN B SULFATE reports
#4 most reported adverse reaction
MACULAR DEGENERATION is the #4 most commonly reported adverse reaction for POLYMYXIN B SULFATE, manufactured by FOSUN PHARMA USA INC. There are 177 FDA adverse event reports linking POLYMYXIN B SULFATE to MACULAR DEGENERATION. This represents approximately 3.5% of all 5,004 adverse event reports for this drug.
Patients taking POLYMYXIN B SULFATE who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is moderately reported among POLYMYXIN B SULFATE users, representing a notable but not dominant share of adverse events.
In addition to macular degeneration, the following adverse reactions have been reported for POLYMYXIN B SULFATE:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 177 FDA reports for POLYMYXIN B SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 3.5% of all adverse event reports for POLYMYXIN B SULFATE, making it a notable side effect.
If you experience macular degeneration while taking POLYMYXIN B SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.